Hypertension after cardiac surgery is common and requires accurate control by carefully regulated infusions of drugs such as sodium nitroprusside. A microprocessor-based controller has been designed to close the loop between the blood pressure response and the infusion rate of a hypotensive drug. This system has been refined by computer simulation of the blood pressure response to sodium nitroprusside and by experience gained in using the controller in eleven patients in the early recovery period after cardiac surgery. The controller was able automatically to maintain blood pressure within 10% of a specified value. Provision of sophisticated safety features in automatic drug infusion controllers is essential for patient protection.
Hypertension is a common complication after cardiac surgery, especially coronary bypass grafting, where the incidence is 30070 to 60%.1. 3 Hypertension is undesirable in the early postoperative period as it may cause haemorrhage from vascular suture lines and the increased afterload may depress cardiac performance. Fremes and colleagues 4 have shown that after cardiac surgery, myocardial recovery is improved if mean arterial blood pressure is carefully maintained between the narrow limits of 90-100 mmHg during the early postoperative period.
The vasodilator sodium nitroprusside (SNP) is the most commonly used agent in the treatment of hypertension after cardiac surgery. When given intravenously, SNP has a short time of onset (20 to 30 seconds) and a half-life of one to two minutes. Although very effective as an intravenous infusion, the rapidity of action and short half-life of SNP cause difficulty in maintaining blood pressure at a steady level.
We have used a microprocessor to close the loop between the infusion of the drug and the blood pressure response, thus allowing blood pressure to be set and maintained at a specified level. The control algorithm has been refined by computer simulation of the hypotensive response to SNP and by experience gained in clinical use after cardiac surgery. DESCRIPTION The Drug Infusion Controller is a microprocessor-based device dedicated to the regulation of vasodilator infusions. It accepts blood pressure signals from standard hospital monitors. The operator enters the desired mean arterial pressure into the controller. The actual and desired mean pressures are compared and an error signal generated, which after suitable processing is used to control an infusion pump ( Figure 1 ). HARDWARE The unit comprises an 8-bit microprocessor, an analogue-to-digital converter and a 2K readonly memory containing the control algorithm. There is also lK of random access memory for temporary storage of data. There are two outputs, which can be connected to a variety of commercially available infusion pumps: a standard 240 volt power socket, and a 5 volt output.
BLOOD
Both outputs are of an on-off nature. The maximum infusion rate of the pump is set manually. The controller regulates the amount of SNP infused into the patient by determining the length of time, the 'on-time', that power is made available to the pump for each sampling period (duty cycle). This form of control is known as pulse width modulation control.
The layout of the front panel is shown in Figure 2 . The digital display can show either the mean arterial pressure or the algorithm constants. A light-emitting diode indicates when the infusion pump is on. One control knob allows desired pressures between 40 and 100 mmHg to be entered and another allows the duty cycle to be set at values between 5 and 20 seconds. There are three recessed controls for altering the algorithm constants, KJ, K2 and K 3 . Two pushbutton controls select parameters to be displayed. SOFTWARE The control algorithm is a modified proportional plus integral regulator which sets on the on-off ratio of a periodic switch. The basal operating state of the pump is set at 66070 of on-time. Thus the steady state infusion rate for zero error is 2/3 of the manually set rate of the pump, thereby allowing a control range of -100070 to + 50070, around the preferred operating point or basal infusion rate. The algorithm has been designed to allow the controller to recover rapidly from situations of large sustained error resulting from such conditions as intermittent hold-up of drug delivery or artifacts in the pressure signal produced by manual flushing of the arterial pressure catheter. Within this algorithm there is provision for accommodating different degrees of patient sensitivity to SNP by manually altering the algorithm constants. An audible alarm is incorporated in the unit to protect against hypotension. If mean arterial pressure falls 20 mmHg below the desired level, the alarm sounds and the infusion is discontinued.
OPERATING PROCEDURE
When the decision to use SNP therapy has been made, an infusion of SNP is set up and the rate of the infusion pump is adjusted manually to bring blood pressure approximately to the desired level. The desired mean arterial pressure is entered into the controller. The infusion pump is then connected to the output from the controller and the infusion rate on the pump is increased 50070 above the rate used for manual control i.e. a rate of 3/2 times the original rate.
Since the controller has a basal operating state of 2/3 of the duty cycle when the error is zero, a 3/2 increase in the nominal pump infusion rate results in an actual infusion rate which is the same as the original manual rate (since 2/3 of 3/2 = 1). Small errors above or below the desired mean arterial pressure will vary the on-time of the pump above or below the 2/3 duty cycle, as required. When the controller is operating correctly, the actual mean arterial pressure averaged over four to five minutes should be the same as the desired mean arterial pressure. The infusion rate will be adjusted automatically to the value required from OOJo to 100% of the pump setting. However, if the controller is operating at one or the other extreme, it is desirable to readjust the pump infusion rate, to restore the on-time to between 114 and 3/4 of the duty cycle. Operating at 100% duty cycle leaves no scope for any required increase in dosage. At the other extreme, i.e. 0% duty cycle, there is a side range of control, but there is increased potential for the patient receiving an excessive dose of drug.
PRE-CLlNICAL TESTS
The Drug Infusion Controller was initially tested in dogs in the laboratory. This enabled obvious technical problems to be detected and eliminated. Next a desk-top computer was used to simulate the human blood pressure control system and the response to SNP. Blood pressure is regulated by complex interaction of many factors. The simple simulation we used was modelled on one described by Slate and colleagues. 5 Two homeostatic mechanisms were simulated, a pressure set point and the reninangiotensin reflex. These two mechanisms provided the background blood pressure which was then modified by variations imposed by simulated respiration. In addition, a small amount of random activity was introduced, which represented non-specific transients in blood pressure. The blood pressure signal resulting from these four factors was then modified by the simulated action of SNP, which took into account the rate of infusion, the patient's sensitivity, the transport delay and the pharmacokinetics of the drug.
CLINICAL EXPERIENCE
The Drug Infusion Controller was tested for one to four hours in eleven patients soon after return to the intensive care ward after open heart surgery. The results in the first four patients showed insufficient control of the blood pressure. Using the simulated patient model, a fault in the algorithm was detected. The algorithm was changed to the form already described, found effective on the patient model then applied in a second series of seven patients. The results were encouraging and showed that the controller could control mean blood pressure within ± 10%, except during major disturbances such as those produced by coughing and straining. Figure 3 shows the action of the Drug Infusion Controller during a period of hypertension occurring soon after cardiac surgery. Desired mean arterial pressure was set at 95 mmHg. Satisfactory control of blood pressure to within ± 10% of desired was achieved except at the times marked C and D. At C the infusion pump was turned off briefly while the reservoir of SNP was refilled. Blood pressure increased steadily until the SNP infusion was recommenced. After resumption of automatic control, blood pressure was rapidly returned to the desired range without 'undershoot'. At D a surge in the arterial pressure signal was caused by back pressure on the transducer while the arterial pressure catheter was being flushed. This was wrongly interpreted by the controller as a rise in the patient's blood pressure. This resulted in an inappropriate temporary increase in SNP dosage. Over the 90 minute period as a whole, there was a steady decline in SNP dosage which indicated a decreasing need for the drug. Mean arterial pressure was maintained constant during this period without manual intervention, by a process of 'automatic weaning' by the controller. Figure 4 shows in more detail another example of the action of the controller. After 3.5 hours of automatic control, the controller was deliberately turned off and the SNP infusion stopped. Mean arterial pressure increased to 120 mmHg within one minute. The controller was then turned back on. The controller initially infused SNP at a high rate, then rapidly reduced the infusion rate to the appropriate level. This resulted in a small 'undershoot', but with return of blood pressure to the desired range within 2.5 minutes. After this initial clinical experience it was felt that unless provision was made to recognise and suppress artifacts in the pressure signal, the controller could not be used without continuous medical supervision. Further clinical trials were deferred pending the production of a new model incorporating this safeguard. The new model, a commercial prototype, is now under construction. * DISCUSSION Accurate control of hypertension is particularly important in the early recovery period after open-heart surgery. Apart from the usual complications which may arise from severe hypertension, such as cerebral haemorrhage, there are added complications after an intracardiac procedure. Postoperative hypertension may cause haemorrhage from incisions in the heart or the aorta. Also hypertension causes an adverse effect on cardiac performance due to increased afterload. This is of special concern in hearts already compromised by longstanding ischaemia or valvular heart disease. Accurate control of hypertension with SNP, though desirable during the early postoperative period, is difficult and time-consuming to achieve manually. Automated control can make the task easier and allow skilled nursing staff to devote more time to other aspects of patient care, which is an important consideration in times of shortage of intensive care nurses.
The basic design requirements for the Drug Infusion Controller were that it be safe, reliable, easy to operate and inexpensive. In this early clinical trial we found that the controller was safe and reliable, but we believe further refining of the algorithm and the incorporation of additional safety features are required.
A major consideration in the control of blood pressure is the presence of a 20-30 second time delay, between the beginning of the SNP infusion and the effect. This delay, together with the one-to two-minute decay constant for SNP and a potentially wide range of patient sensitivities, led us to use a conservative control algorithm which aims to counter disturbances in mean arterial pressure within two minutes. It is important to recognise that SNP therapy cannot eliminate short-term variations in mean arterial pressure which occur over periods of less than two minutes. However, variations occurring over five minutes or more can be eliminated almost completely by appropriate automatic control.
The decision to use pulse width modulation control to regulate standard hospital infusion pumps is in keeping with a design philosophy that medical and nursing personnel be conscious of having final control over the maximum infusion rate, a factor which greatly increases safety and user acceptance.
In contrast to most previously described systems which use general purpose computers or microprocessors 6 . s , this infusion controller is a dedicated unit which takes up little space at the bedside. Simplicity of operation is important not only in terms of safety, but also in determining whether the controller is readily accepted by nursing and medical staff. Since the only adjustment normally required before operating this unit is to set the desired pressure, acceptance of this system is more likely than those based on general purpose microcomputers which usually require more complicated entries of parameters and instructions via a computer keyboard. Also compatibility with existing hospital equipment minimises cost and reduces disturbance to existing nursing practices.
Plans are underway to increase the safety and convenience of the controller in an improved version now under construction. This will have the necessary software to recognise and reject artifacts in the pressure input signal produced by kinking or flushing the arterial pressure monitoring catheter. Another safety feature being incorporated is a self test, which shuts down the controller in the unlikely event of microprocessor failure. Ultimately, it is hoped that the controller will have an adaptive control algorithm similar to that described by Arnsparger,9 which enables the controller to learn about the patient's responsiveness as it controls the blood pressure and to adjust the gain of the controller automatically.
At the moment the Drug Infusion Controller has only been used for postoperative hypertension. We envisage that in the future, automatic controllers may play a role in the management of other types of acute hypertension such as malignant hypertension or hypertension of pregnancy. Another possible application is in the production of deliberate hypotension, for example during neurosurgical procedures. SNP therapy is being used increasingly in the treatment of acute cardiac failure by afterload reduction. Automatic control may have a role in this situation by preventing undesirable hypotension. Also controllers may be adapted for use with drugs which raise blood pressure such as adrenaline or dopamine.
In conclusion, dedicated microprocessorbased infusion controllers can combine the advantages of convenience and ease of use, with safety and economy. We believe they show promise for widespread use in the future.
